Shin-ichi. Oka, et.al., Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome., FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, 20

http://rdf.ncbi.nlm.nih.gov/pubmed/16254043

Shin-ichi. Oka, et.al., Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome., FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, 20

pubmed

allele

http://purl.org/net/cito/citesAsAuthority

• Txnip<tm1Jjy>
  http://metadb.riken.jp/db/mgi_rdf/MGI:3613036

class

http://purl.org/net/cito/citesAsAuthority

• Txnip<tm1Jjy>
  http://metadb.riken.jp/db/mgi_rdf/MGI:3613036

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• hepatic steatosis_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0002628IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• increased circulating ketone body level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0002575IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• abnormal lipid homeostasis_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0002118IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• abnormal glucose homeostasis_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0002078IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• abnormal blood homeostasis_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0009642IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• abnormal circulating insulin level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0001560IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• abnormal circulating phospholipid level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0006084IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• decreased circulating glucose level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0005560IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• increased circulating potassium level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0005627IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• increased circulating free fatty acid level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0001554IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• increased blood urea nitrogen level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0005565IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• decreased circulating antithrombin level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0012325IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• kidney failure_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0003606IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• increased bleeding time_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0005606IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• increased circulating triglyceride level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0001552IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• increased sensitivity to induced morbidity/mortality_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0009763IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• liver degeneration_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0003103IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• increased circulating cholesterol level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0005178IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• decreased circulating sodium level_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0005634IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• hematuria_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0005161IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• increased prothrombin time_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0012356IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy
• increased partial thromboplastin time_Txnip<tm1Jjy>/Txnip<tm1Jjy>
  http://metadb.riken.jp/0012359IC57BL6CBATxniptm1JjyTxniptm1JjyTxniptm1Jjy